 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

Market Cap	$405.22M
52-Wk High	$7.55
52-Wk Low	$7.55

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$7.55
Beta	0.00
Avg. Volume	0.05
PE Ratio	-10.42

52-Week High	$7.55
52-Week Low	$7.55
Market Capitalization	$405.22M
EPS	-$0.5198
Price to Book	7.13
Revenue Per Employee	$609,754.35
Enterprise Value/EBITDA	N/A

CLTEF Calliditas Therapeutics AB - Ordinary Shares - Class B

About

Feed

News

Earnings

Fundamentals